Trial | NCT01850420  Report issue

Title

A Study of IMC-1 In Patients With Fibromyalgia
A Double-Blinded, Randomized, Placebo-Controlled, Proof of Concept Phase 2a Study Exploring the Safety and Efficacy of IMC-1 for the Treatment of Patients With Fibromyalgia

  • Phase

    Phase 2

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    imc-1 ...

  • Study Participants

    143
This is a randomized, double-blind, placebo-controlled, 16-week study designed to evaluate the hypothesis that tissue-resident herpes virus may be causally related to fibromyalgia symptoms or recurrence. IMC-1 is a combination treatment that is designed to suppress this suspected virus and thus alleviate fibromyalgia symptoms.
Study Started
May 31
2013
Primary Completion
Jan 31
2014
Study Completion
Mar 31
2014
Last Update
Mar 27
2015
Estimate

Drug IMC-1

IMC-1 Experimental

Experimental intervention

Matching placebo Placebo Comparator

Criteria 

Inclusion Criteria:

Diagnosis of fibromyalgia
English speaker

Exclusion Criteria:

Rheumatologic diseases
Bipolar disease, OCD, severe anxiety, schizophrenia
Systemic infection, severe cardiac disease, chronic steroid usage
chronic opioid usage
No Results Posted